These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 11012377

  • 1. In vitro characterization of a novel factor Xa inhibitor, RPR 130737.
    Chu V, Brown K, Colussi D, Choi YM, Green D, Pauls HW, Spada AP, Perrone MH, Leadley RJ, Dunwiddie CT.
    Thromb Res; 2000 Jul 01; 99(1):71-82. PubMed ID: 11012377
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological characterization of a novel factor Xa inhibitor, FXV673.
    Chu V, Brown K, Colussi D, Gao J, Bostwick J, Kasiewski C, Bentley R, Morgan S, Guertin K, Pauls HW, Gong Y, Zulli A, Perrone MH, Dunwiddie CT, Leadley RJ.
    Thromb Res; 2001 Aug 15; 103(4):309-24. PubMed ID: 11562341
    [Abstract] [Full Text] [Related]

  • 3. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
    Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T.
    J Thromb Haemost; 2008 Sep 15; 6(9):1542-9. PubMed ID: 18624979
    [Abstract] [Full Text] [Related]

  • 4. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M, Konishi N, Hiroe K, Shofuda K, Imaeda Y, Fujimoto T, Kubo K.
    J Cardiovasc Pharmacol; 2010 Aug 15; 56(2):156-61. PubMed ID: 20410831
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X, Xiao Y, Yu C, Zuo Y, Yang W, Wang X, Gu B, Li J.
    Eur J Pharmacol; 2018 Apr 15; 825():85-91. PubMed ID: 29475063
    [Abstract] [Full Text] [Related]

  • 6. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC, Jiang X.
    Thromb Haemost; 2010 Aug 15; 104(2):302-10. PubMed ID: 20589316
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
    Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A.
    J Thromb Haemost; 2005 Mar 15; 3(3):514-21. PubMed ID: 15748242
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
    Prasa D, Svendsen L, Stürzebecher J.
    Thromb Haemost; 1997 Oct 15; 78(4):1215-20. PubMed ID: 9364987
    [Abstract] [Full Text] [Related]

  • 9. Ecotin is a potent anticoagulant and reversible tight-binding inhibitor of factor Xa.
    Seymour JL, Lindquist RN, Dennis MS, Moffat B, Yansura D, Reilly D, Wessinger ME, Lazarus RA.
    Biochemistry; 1994 Apr 05; 33(13):3949-58. PubMed ID: 8142399
    [Abstract] [Full Text] [Related]

  • 10. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y, Kamisato C, Morishima Y.
    Thromb Res; 2016 May 05; 141():17-21. PubMed ID: 26962981
    [Abstract] [Full Text] [Related]

  • 11. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
    Deinum J, Mattsson C, Inghardt T, Elg M.
    Thromb Haemost; 2009 Jun 05; 101(6):1051-9. PubMed ID: 19492147
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.
    Leblond L, Grouix B, Boudreau C, Yang Q, Siddiqui MA, Winocour PD.
    Thromb Res; 2000 Nov 01; 100(3):195-209. PubMed ID: 11108907
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of thrombin and other trypsin-like serine proteinases by cyclotheonamide A.
    Lewis SD, Ng AS, Baldwin JJ, Fusetani N, Naylor AM, Shafer JA.
    Thromb Res; 1993 Apr 15; 70(2):173-90. PubMed ID: 8322286
    [Abstract] [Full Text] [Related]

  • 14. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard JA, Ofosu FA.
    Thromb Haemost; 2005 Nov 15; 94(5):958-64. PubMed ID: 16363236
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT, Depasse F, Chakroun T, Van Dreden P, Samama MM, Elalamy I.
    Blood Coagul Fibrinolysis; 2004 Mar 15; 15(2):149-56. PubMed ID: 15091002
    [Abstract] [Full Text] [Related]

  • 16. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
    Tobu M, Iqbal O, Hoppensteadt DA, Shultz C, Jeske W, Fareed J.
    Clin Appl Thromb Hemost; 2002 Oct 15; 8(4):325-36. PubMed ID: 12516682
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.